Early in the coronavirus vaccine race, Novavax (NASDAQ: NVAX) shares soared. The stock finished 2020 with a 2,700% gain. Investors cheered on this company's program -- and bet that it would be among the first to launch a vaccine. When Novavax's program fell behind, though, so did the stock. Today, Novavax shares are trading for less than even the very lowest Wall Street 12-month price estimate.
Meanwhile, Novavax won authorization for its vaccine in more than 35 countries in recent months. And the company is leading in the development of an important potential product: a combined flu/coronavirus vaccine. Does this mean Novavax is a good buy now? Or are this company's best days in the past? Let's take a close look at Novavax's latest news and what may be on the horizon before deciding.
Image source: Getty Images.
Source Fool.com